Per Wold-Olsen
Retired President, Human Health Intercontinental Division, Merck & Co., Inc.
Per Wold-Olsen joined our Board in January 2010, after serving as the Chair of Gilead’s Health Policy Advisory Board since 2007. From 2005 to 2006, he served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck. Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S. He also serves as Chairman of the Board of Oncopeptides AB. Mr. Wold-Olsen is Chair of the Board of the Medicines for Malaria Venture (MMV), a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria.
-
Daniel O’Day
Chairman and Chief Executive Officer
-
Jacqueline K. Barton, PhD
Professor, California Institute of Technology
-
John F. Cogan, PhD
Lead Independent Director, Gilead Sciences
-
Kelly A. Kramer
Executive Vice President and Chief Financial Officer, Cisco Systems, Inc.
-
Kevin E. Lofton
Chief Executive Officer, CommonSpirit Health
-
Harish Manwani
Retired Chief Operating Officer, Unilever
-
George P. Shultz
Director Emeritus, Gilead Sciences
-
Richard J. Whitley, MD
Distinguished Professor, Loeb Scholar Chair in Pediatrics, Professor of Pediatrics, Microbiology, Medicine, and Neurosurgery, University of Alabama at Birmingham
-
Gayle E. Wilson
Chairman Emeritus of COSMOS, The California State Summer School for Math and Science
-
Per Wold-Olsen
Retired President, Human Health Intercontinental Division, Merck & Co., Inc.